Decision Resources and Millennium Research Group have produced a new report that finds that Gilead is overtaking GlaxoSmithKline (GSK) as the number one HIV drug company thanks to an innovative product portfolio that includes Atripla, a fixed-dose combination of Gilead's Truvada and Bristol-Myers Squibb (BMS)/Merck's Sustiva creating the first complete one-pill, once-daily HIV therapy. Furthermore, the report finds that Atripla is the top-of-mind antiretroviral among HIV specialists and is the product most requested by patients. Surveyed HIV specialists also indicated that GSK and Gilead were the two top-of-mind companies with regards to HIV treatment.

"Not surprisingly, physicians ranked quality of a company's marketed products as the most important factor in determining their impression of a company, but effective clinical trial design, both pre- and postmarketing, is also very important to physicians' perception, as is product innovation," said Craig Speziali, analyst at Millennium Research Group. "Gilead was ranked 'best' on six of ten factors surveyed, most notably on quality of products."

With two products (Pfizer's Selzentry and Merck's Isentress) from completely novel antiretroviral classes entering the market in 2007, the study also evaluates physician perception and expected use of these products in various scenarios. Both drugs feature novel mechanisms of action and will therefore be competing for use among patients with limited treatment options; however, it will not necessarily be the case that a physician chooses one drug over the other because coadministration of Selzentry and Isentress may well occur in some patients who lack viable alternatives.

About Brands & Strategies

Brands & Strategies is the first and only report series to bring together all of the competitive information elements biopharmaceutical companies need to make informed decisions about their products and the best next-steps. Each report includes the following:

  -- Brand-specific, event-driven, five-year annualized market forecast.   -- Country-specific market share projections by brand and assessment of      impacts of future events.   -- Drug class sales by country.   -- Brand sales by region.   -- Projected price for all drugs for five years.   -- Generic pricing impact on all drugs.   -- Prevalence and diagnosis rates by country.   -- Promotional spend for each product.   -- Pipeline analysis by company within a specific disease.   -- SWOT analysis on each brand.   -- Clinical trial reviews and clinical trial competitive analysis.   -- Detailed brand strategy and how it relates to clinical trial results.   -- Impact of Medicare.   -- Selling strategies based on clinical trials.    About Millennium Research Group 

Millennium Research Group (, part of the Decision Resources, Inc., family, is a leading provider of strategic information to the healthcare sector. Focused on the medical device, pharmaceutical, and biotechnology industries, the company provides clients its specialized industry expertise through published reports and customized consulting services.

About Decision Resources

Decision Resources, Inc., ( is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-

Launch of Drugs from Medarex/Bristol-Myers Squibb and Pfizer Will Significantly Impact the Market for Treatment of Malignant Melanoma

View Now